Enterprise Value

-14.93M

Cash

174.5M

Avg Qtr Burn

-14.01M

Short % of Float

6.18%

Insider Ownership

1.19%

Institutional Own.

48.60%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 2

Data readout

CX-801 Details
Cancer, Solid tumor/s, Melanoma, Renal cell carcinoma, Head and neck squamous cell carcinoma

Phase 1

Initiation

Phase 1

Initiation

CX-904 (EGFRxCD3) Details
Cancer, Solid tumor/s

Phase 1a

Data readout

CX-2029 (PDC directed against CD71) Details
Non-small cell lung carcinoma, Head and neck squamous cell carcinoma, Cancer, Solid tumor/s

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued

Praluzatamab ravtansine (CX-2009) (anti-CD166) Details
Cancer, HER2-expressing cancers, Breast cancer

Failed

Discontinued